|
1
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
Male:female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Krause DS and Van Etten RA: Tyrosine
kinases as targets for cancer therapy. N Engl J Med. 353:172–187.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hynes NE and Lane HA: ERBB receptors and
cancer: The complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaneda T, Hata A, Tomioka H, Tanaka K,
Kaji R, Fujita S, Tomii K and Katakami N: Possible differential
EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant
non-small cell lung cancer. Lung Cancer. 86:213–218. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Girgenrath M, Weng S, Kostek CA, Browning
B, Wang M, Brown SA, Winkles JA, Michaelson JS, Allaire N,
Schneider P, et al: TWEAK, via its receptor Fn14, is a novel
regulator of mesenchymal progenitor cells and skeletal muscle
regeneration. EMBO J. 25:5826–5839. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baxter FO, Came PJ, Abell K, Kedjouar B,
Huth M, Rajewsky K, Pasparakis M and Watson CJ: IKKbeta/2 induces
TWEAK and apoptosis in mammary epithelial cells. Development.
133:3485–3494. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Winkles JA: The TWEAK-Fn14
cytokine-receptor axis: Discovery, biology and therapeutic
targeting. Nat Rev Drug Discov. 7:411–425. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burkly LC, Michaelson JS and Zheng TS:
TWEAK/Fn14 pathway: An immunological switch for shaping tissue
responses. Immunol Rev. 244:99–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y,
Kim DI, Park YB, Kwon BS, Park JE and Lee WH: TWEAK can induce
pro-inflammatory cytokines and matrix metalloproteinase-9 in
macrophages. Circ J. 68:396–399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pettersen I, Baryawno N, Abel F, Bakkelund
WH, Zykova SN, Winberg JO, Moens U, Rasmuson A, Kogner P, Johnsen
JI, et al: Expression of TWEAK/Fn14 in neuroblastoma: implications
in tumorigenesis. Int J Oncol. 42:1239–1248. 2013.PubMed/NCBI
|
|
13
|
Lynch CN, Wang YC, Lund JK, Chen YW, Leal
JA and Wiley SR: TWEAK induces angiogenesis and proliferation of
endothelial cells. J Biol Chem. 274:8455–8459. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harada N, Nakayama M, Nakano H, Fukuchi Y,
Yagita H and Okumura K: Pro-inflammatory effect of TWEAK/Fn14
interaction on human umbilical vein endothelial cells. Biochem
Biophys Res Commun. 299:488–493. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chicheportiche Y, Chicheportiche R, Sizing
I, Thompson J, Benjamin CB, Ambrose C and Dayer JM: Proinflammatory
activity of TWEAK on human dermal fibroblasts and synoviocytes:
Blocking and enhancing effects of anti-TWEAK monoclonal antibodies.
Arthritis Res. 4:126–133. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Whitsett TG, Cheng E, Inge L, Asrani K,
Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner
R, et al: Elevated expression of Fn14 in non-small cell lung cancer
correlates with activated EGFR and promotes tumor cell migration
and invasion. Am J Pathol. 181:111–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chapman MS, Wu L, Amatucci A, Ho SN and
Michaelson JS: TWEAK signals through JAK-STAT to induce tumor cell
apoptosis. Cytokine. 61:210–217. 2013. View Article : Google Scholar
|
|
18
|
Gastl G, Spizzo G, Obrist P, Dünser M and
Mikuz G: Ep-CAM overexpression in breast cancer as a predictor of
survival. Lancet. 356:1981–1982. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao J, Zhou Y, Zhang Z, Tian F, Ma N, Liu
T, Gu Z and Wang Y: Upregulated fascin1 in non-small cell lung
cancer promotes the migration and invasiveness, but not
proliferation. Cancer Lett. 290:238–247. 2010. View Article : Google Scholar
|
|
20
|
Kwon OH, Park SJ, Kang TW, Kim M, Kim JH,
Noh SM, Song KS, Yoo HS, Wang Y, Pocalyko D, et al: Elevated
fibroblast growth factor-inducible 14 expression promotes gastric
cancer growth via nuclear factor-κB and is associated with poor
patient outcome. Cancer Lett. 314:73–81. 2012. View Article : Google Scholar
|
|
21
|
Zhou H, Ekmekcioglu S, Marks JW,
Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB,
Hittelman WN, et al: The TWEAK receptor Fn14 is a therapeutic
target in melanoma: Immunotoxins targeting Fn14 receptor for
malignant melanoma treatment. J Invest Dermatol. 133:1052–1062.
2013. View Article : Google Scholar
|
|
22
|
Huang M, Narita S, Tsuchiya N, Ma Z,
Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et
al: Overexpression of Fn14 promotes androgen-independent prostate
cancer progression through MMP-9 and correlates with poor treatment
outcome. Carcinogenesis. 32:1589–1596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Townsend PA, Scarabelli TM, Davidson SM,
Knight RA, Latchman DS and Stephanou A: STAT-1 interacts with p53
to enhance DNA damage-induced apoptosis. J Biol Chem.
279:5811–5820. 2004. View Article : Google Scholar
|
|
24
|
Stephanou A, Brar BK, Knight RA and
Latchman DS: Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and
Bcl-x promoters. Cell Death Differ. 7:329–330. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chin YE, Kitagawa M, Kuida K, Flavell RA
and Fu XY: Activation of the STAT signaling pathway can cause
expression of caspase 1 and apoptosis. Mol Cell Biol. 17:5328–5337.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumar A, Commane M, Flickinger TW, Horvath
CM and Stark GR: Defective TNF-alpha-induced apoptosis in
STAT1-null cells due to low constitutive levels of caspases.
Science. 278:1630–1632. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fryknäs M, Dhar S, Oberg F, Rickardson L,
Rydåker M, Göransson H, Gustafsson M, Pettersson U, Nygren P,
Larsson R, et al: STAT1 signaling is associated with acquired
crossresistance to doxorubicin and radiation in myeloma cell lines.
Int J Cancer. 120:189–195. 2007. View Article : Google Scholar
|
|
28
|
Roberts D, Schick J, Conway S, Biade S,
Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ and Johnson SW:
Identification of genes associated with platinum drug sensitivity
and resistance in human ovarian cancer cells. Br J Cancer.
92:1149–1158. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zimmer S, Kahl P, Buhl TM, Steiner S,
Wardelmann E, Merkelbach-Bruse S, Buettner R and Heukamp LC:
Epidermal growth factor receptor mutations in non-small cell lung
cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer
Res Clin Oncol. 135:723–730. 2009. View Article : Google Scholar
|
